06378nam 2201801z- 450 991055744870332120210501(CKB)5400000000043253(oapen)https://directory.doabooks.org/handle/20.500.12854/68969(oapen)doab68969(EXLCZ)99540000000004325320202105d2020 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierAntiviral AgentsBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20201 online resource (386 p.)3-03928-953-5 3-03928-954-3 Antiviral agents are used for the treatment of viral diseases. Antiviral drugs have been successfully developed and used clinically for a limited number of important human viral diseases notably caused by human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), herpes, and influenza viruses. Despite the successes of these antiviral drugs, issues with drug resistance and toxicity remain challenging. These challenges are driving research to identify new drug candidates and to investigate novel drug targets to develop new mechanistic drug classes. Antiviral agents are not available against many viruses that cause human disease and economic burdens; in particular, the development of antiviral agents against emerging, re-emerging, and neglected viruses is increasingly becoming a priority. This book includes six review articles that discuss new antiviral strategies. The reviews either discuss advances relating to a specific virus or new therapeutic targets and approaches. The book includes 15 original research articles reporting new antiviral agents against a variety of clinically and economically important viruses and studies into the prevalence or acquisition of drug resistance. Overall, this book is an exciting collection of new research and ideas relating to the development of antiviral agents.Biology, life sciencesbicsscResearch and information: generalbicsscacteosideacute/latent infectionacycloviradoptive cell therapyantipsychotic drugantiviralantiviral activityantiviral agentantiviral agentsantiviral drugantiviral effectantiviral inhibitorantiviral strategiesbranched peptidesbrevilin ABurkitt lymphoma cellsC-FRAcathelicidinscentral nervous systemchemical footprintingClerodendrum trichotomumclozapinecombination antiretroviral therapy (cART)congenital infectioncoxsackievirus B4CRISPR/Cascytomegalovirusdefensinsdried blood spotsdried plasma spotsdrug discoveryendocytosisenterovirusesepigallocatechin gallateEpstein-Barr virusEthiopiaflavivirusflavonoidsfluoxetinefurin inhibitorganciclovirgenisteinginsenoside Rg1glycosphingolipidsHCMV vaccinehemagglutinin (HA)heparan sulfatehepatitis C virushepcidinsherpes B virusherpes virusesherpesvirusHIVhuman antimicrobial peptideshuman immunodeficiency virusie-1 geneIE1IE2immediate-earlyinfluenza A virusinfluenza A virus (IAV)Japanese encephalitis viruslatent infectionlectinlipid biosynthesisLUMS1lytic gene expressionmacacine herpesvirus-1measles virusmicrovirinmutationsn/aneural stem cellsNF-κB signaling pathwaynon-immunogenicNS5nucleic acid-based therapeutic approachnucleoside analoguesoleanane-type derivativesorthohantaviruspediatricsPEIpersistent infectionphenyl-benzotriazolesPlantago asiaticapolyethyleniminePorcine circovirus type 2porcine reproductive and respiratory syndrome viruspre-treatment drug resistanceprecursor membrane proteinpro-inflammatory factorprodrugsprotein drugsProTidesPRRSVquantitative real-time PCRreplicationresistanceRev response elementribozymeRNA interferenceRNA-dependent RNA polymeraseRSVsesquiterpene lactoneSHAPEsmall moleculesphingolipidsSurveyor nuclease mutation detection assayTALENtherapeutic effectstherapeutic strategiestransferrinstreatmentstropismviral entryvirion internalizationvirus attachmentvirus entry inhibitorsvirusesZika virusBiology, life sciencesResearch and information: generalAdamson Catherineedt1323411Adamson CatherineothBOOK9910557448703321Antiviral Agents3035519UNINA